Literature DB >> 18460344

Targeting DNA with triplex-forming oligonucleotides to modify gene sequence.

Philippe Simon1, Fabio Cannata, Jean-Paul Concordet, Carine Giovannangeli.   

Abstract

Molecules that interact with DNA in a sequence-specific manner are attractive tools for manipulating gene sequence and expression. For example, triplex-forming oligonucleotides (TFOs), which bind to oligopyrimidine.oligopurine sequences via Hoogsteen hydrogen bonds, have been used to inhibit gene expression at the DNA level as well as to induce targeted mutagenesis in model systems. Recent advances in using oligonucleotides and analogs to target DNA in a sequence-specific manner will be discussed. In particular, chemical modification of TFOs has been used to improve binding to chromosomal target sequences in living cells. Various oligonucleotide analogs have also been found to expand the range of sequences amenable to manipulation, including so-called "Zorro" locked nucleic acids (LNAs) and pseudo-complementary peptide nucleic acids (pcPNAs). Finally, we will examine the potential of TFOs for directing targeted gene sequence modification and propose that synthetic nucleases, based on conjugation of sequence-specific DNA ligands to DNA damaging molecules, are a promising alternative to protein-based endonucleases for targeted gene sequence modification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460344     DOI: 10.1016/j.biochi.2008.04.004

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  29 in total

Review 1.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 2.  Potential in vivo roles of nucleic acid triple-helices.

Authors:  Fabian A Buske; John S Mattick; Timothy L Bailey
Journal:  RNA Biol       Date:  2011-05-01       Impact factor: 4.652

3.  Optimized DNA-targeting using triplex forming C5-alkynyl functionalized LNA.

Authors:  Sujay P Sau; Pawan Kumar; Brooke A Anderson; Michael E Østergaard; Lee Deobald; Andrzej Paszczynski; Pawan K Sharma; Patrick J Hrdlicka
Journal:  Chem Commun (Camb)       Date:  2009-10-12       Impact factor: 6.222

Review 4.  Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers.

Authors:  Asuka Eguchi; Garrett O Lee; Fang Wan; Graham S Erwin; Aseem Z Ansari
Journal:  Biochem J       Date:  2014-09-15       Impact factor: 3.857

Review 5.  Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): tools for fundamental research, diagnostics, and nanotechnology.

Authors:  Michael E Østergaard; Patrick J Hrdlicka
Journal:  Chem Soc Rev       Date:  2011-04-13       Impact factor: 54.564

Review 6.  Oligo/polynucleotide-based gene modification: strategies and therapeutic potential.

Authors:  R Geoffrey Sargent; Soya Kim; Dieter C Gruenert
Journal:  Oligonucleotides       Date:  2011-03-21

Review 7.  Repair of DNA lesions associated with triplex-forming oligonucleotides.

Authors:  Joanna Y Chin; Peter M Glazer
Journal:  Mol Carcinog       Date:  2009-04       Impact factor: 4.784

8.  Recognition of mixed-sequence DNA duplexes: design guidelines for invaders based on 2'-O-(pyren-1-yl)methyl-RNA monomers.

Authors:  Saswata Karmakar; Dale C Guenther; Patrick J Hrdlicka
Journal:  J Org Chem       Date:  2013-11-20       Impact factor: 4.354

9.  Functionalized 2'-amino-alpha-L-LNA: directed positioning of intercalators for DNA targeting.

Authors:  T Santhosh Kumar; Andreas S Madsen; Michael E Østergaard; Sujay P Sau; Jesper Wengel; Patrick J Hrdlicka
Journal:  J Org Chem       Date:  2009-02-06       Impact factor: 4.354

10.  In vitro selection of oligonucleotides that bind double-stranded DNA in the presence of triplex-stabilizing agents.

Authors:  Elodie Ayel; Christophe Escudé
Journal:  Nucleic Acids Res       Date:  2009-12-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.